Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 07/27 05:31:21 pm
81.9 CHF   -0.73%
10:56pDJAmgen Profit Rises 13%, 2016 Outlook Raised
02:06pDJGLAXOSMITHKLINE : Helped and Hurt by Sterling's Post-Brexit Fall
03:05a NOVARTIS : Guidepost Solutions Appoints Sokolow Former Novartis Serv..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CEST

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
10:56pDJAmgen Profit Rises 13%, 2016 Outlook Raised
02:06pDJGLAXOSMITHKLINE : Helped and Hurt by Sterling's Post-Brexit Fall
03:05a NOVARTIS : Guidepost Solutions Appoints Sokolow Former Novartis Services General..
07/26 ELI LILLY : New Animal Drugs; Change of Sponsor
07/26DJEli Lilly Revenue Rise Helped by New Products
07/25DJSTADA ARZNEIMITTEL : Feels More Heat From Active Ownership
07/22 NOVARTIS : IGI Securities Limited - Investor Kit
07/21 NOVARTIS : Patent Issued for Compounds Containing S-N-Valeryl-N-{-Methyl)-Valine..
07/21 NOVARTIS : IGI Securities Limited - Investor Kit
07/20DJBusiness Watch -- WSJ
More news
Sector news : Pharmaceuticals - NEC
11:00pDJALERE : Faces Criminal Probe Over Medicare, Medicaid Billing -- Update
10:56pDJAmgen Profit Rises 13%, 2016 Outlook Raised
10:56pDJAlere Faces Criminal Probe Over Medicare, Medicaid Billing
10:36pDJFacebook Profit, Revenue Jump as Advertisers Flock to Social Network
09:45p Teva purchase of Allergan generics business gets OK with conditions
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/26 Generics Keeping The Pressure On Big Pharma
07/25 FDA removes clinical hold on early-stage study of Novartis' hearing loss cand..
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/22 Biogen Needs To Fill Pipeline Or Rethink Strategy
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
Advertisement
Financials ($)
Sales 2016 48 844 M
EBIT 2016 11 400 M
Net income 2016 7 496 M
Debt 2016 14 301 M
Yield 2016 3,41%
P/E ratio 2016 24,16
P/E ratio 2017 21,93
EV / Sales 2016 4,80x
EV / Sales 2017 4,64x
Capitalization 219 971 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 90,0 $
Spread / Average Target 8,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-5.30%219 971
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
ROCHE HOLDING LTD.-9.99%218 902
MERCK & CO., INC.10.49%161 542
BRISTOL-MYERS SQUIBB C..9.11%125 298
More Results